Latest News Our latest news and industry chatter Latest News Our latest news and industry chatter
News from Blueberry Therapeutics2021-04-21T13:54:04+00:00
2311, 2018

CEO to attend the Dermatology Drug Development Summit in Boston

November 23rd, 2018|

Blueberry CEO, John Ridden, will be attending the 2nd Dermatology Drug Development Summit in Boston, 27-29th November 2018. The event is a unique industry-led conference focusing on innovating & accelerating the development amd commercialisation of dermatological medicines.

1110, 2018

CSO David Cook presents at ELRIG Drug Discovery Conference

October 11th, 2018|

David Cook presented at the recent ELRIG (European Laboratory Research and Innovation group) Drug Discovery Conference. David was invited to present in a workshop called “Build Biotech Success: A practical case study with CROs at Alderley Park”. The session focused [...]

1408, 2018

Blueberry Therapeutics Limited closes £10m funding to support development of nanomedicines portfolio

August 14th, 2018|

Alderley Park, UK, 14 August 2018– Blueberry Therapeutics Limited, (“Blueberry Therapeutics”) a drug discovery and development company focused on developing innovative nanomedicines for difficult to treat skin and nail infections, today announces that it has successfully completed its £10m [...]

2905, 2018

CEO attending BIO International, Boston

May 29th, 2018|

John Ridden, Blueberry CEO will be attending BIO International convention in Boston, 4th-7th June. 2018 is the 25th year for the BIO Convention, and attracts more than 16,000 biotechnology and pharma leaders who come together for one week of [...]

2004, 2018

Blueberry CEO, CSO and FD to attend BioTrinity London 23-25 April

April 20th, 2018|

John Ridden, David Cook and Mark Hollingworth will be attending BioTrinity London 23-25 April. BioTrinity is Europe’s leading biopartnering and investment conference, and is in its 12thconsecutive year. The theme for 2018 is “Next Generation Healthcare”. We look forward to [...]

611, 2017

CEO presents to Chinese investors and companies

November 6th, 2017|

John Ridden, CEO of Blueberry Therapeutics, recently presented at the UK-China Life Science Event run by the DIT (Department for International Trade). The event was hosted by Lancaster University and is an opportunity for Life Science companies in the [...]

2906, 2017

CEO John Ridden presents at Biofocus 2017

June 29th, 2017|

Blueberry Therapeutics CEO John Ridden presented at the Biofocus 2017 event at the Centre for Life in Newcastle upon Tyne as part of the Industry Showcase session. The Biofocus event is an annual event bringing together industry academia and experts [...]

1805, 2017

David Cook presents at ELRIG

May 18th, 2017|

CSO David Cook presented at the recent ELRIG (European Laboratory Research & Innovation Group) held at Alderley Park. David presented as part of a diverse evening of seminars on the topic “Novel Approaches to Meeting the Challenges of Antimicrobial Drug [...]

1603, 2017

Blueberry in the news again!

March 16th, 2017|

Blueberry's CEO John Ridden was interviewed by Times writer Michael Cape. John and Michael spoke about how Blueberry benefitted from AstraZeneca's move to Cambridge, which led to husband and wife team David and Julie Cook (CSO and Principal Scientist) [...]

803, 2017

Blueberry hold their first Site Initiation Visit in Berlin

March 8th, 2017|

The Blueberry Clinical Team, consisting of Dr Mike Davies, co-founder and Chief Medical Officer, Mark Sidaway, Clinical Project Manager and Jane Davies, Senior CRA, held their site initiation visit (SIV) at the Parexel Early Phase Clinical Unit in Berlin, [...]

1301, 2017

Blueberry Therapeutics hosts a seminar on nail diseases

January 13th, 2017|

Blueberry Therapeutics was pleased to host Dr. Sudax Murdan from University College London. Sudax is a world expert in disease of the nail and topical drug delivery. Sudax spent the day with the Blueberry team including her excellent seminar on [...]

1411, 2016

Blueberry CSO presents at Superbugs & Superdrugs conference

November 14th, 2016|

CSO David Cook presents at the “Superbugs & Supderdrugs” conference held in Iselin, USA. The conference brought together experts in anti-microbial drug resistance from Government, Pharma and Biotech. David gave a presentation on “Targeting Mechanisms of Resistance Using Protein Resistance [...]

Go to Top